<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[pivotal corp. Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/pivotal+corp..html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to pivotal corp.]]></description>
	<s:counts start="0" returned="20" found="1232" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Pivotal Makes First Investment in Solar, Bets Small and Strategic on Northwest Cleantech]]></title>
		<link><![CDATA[http://industry.bnet.com/energy/news-analysis/pivotal-investment-solar-bets-strategic/9607/]]></link>
		<description><![CDATA[On Tuesday, we reported that Pivotal Investments has led a $2 million financing round for Tuusso Energy, a solar power developer based in Seattle. Tuusso is an intriguing startup focused on developing and operating solar plants to supply renewable energy to utility companies; its first plant is slated to be...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Thu, 27 Aug 2009 19:07:44 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/clean+technology.html"><![CDATA[clean technology]]></category>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
	</item>
	<item>
		<title><![CDATA[Pivotal season awaits]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_kmusa/is_200810/ai_n30919471]]></link>
		<description><![CDATA[NEW YORK -- Madison Square Garden is nestled among Manhattan's midtown skyscrapers at Two Pennsylvania Plaza, an address some basketball fans consider hallowed ground. But for the last seven seasons, the New York Knicks have done little to consecrate their home. In that time the Knicks have failed to deliver...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 16 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/madison+square+garden+l.p..html"><![CDATA[Madison Square Garden L.P.]]></category>
		<category domain="http://resources.bnet.com/topic/nba.html"><![CDATA[NBA]]></category>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[ACM-Pivotal Offers Eco-Friendly Branding Solutions for Pharma Commercialization Efforts]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Sept_22/ai_n28575306]]></link>
		<description><![CDATA[Customized Specimen Collection Kits Provide Convenience, Accuracy and Promotion Ideal for Post-Marketing Studies  ROCHESTER, N.Y. -- ACM-Pivotal, the global central laboratory that continually defines the customer-service standard with its flexible approach, is now offering its unique KitKaddySM and lab collection kits to pharmaceutical, biotech and contract research organizations CROs...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 22 Sep 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/acm.html"><![CDATA[ACM]]></category>
		<category domain="http://resources.bnet.com/topic/brand.html"><![CDATA[brand]]></category>
		<category domain="http://resources.bnet.com/topic/branding.html"><![CDATA[Branding]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[MARKETING]]></category>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Javelin Presents Successful Pivotal Phase 3 Secondary Clinical Results for Dyloject&#153; at the 12th World Congress on Pain]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_August_21/ai_n28024848]]></link>
		<description><![CDATA[GLASGOW, Scotland -- Javelin Pharmaceuticals, Inc. (Amex: JAV), a leading developer of novel products for pain management, today presented new and successful secondary endpoint data from a previously announced pivotal Phase 3 study of Dyloject([TM]). At the 12th World Congress on Pain, held in Glasgow, Scotland. Dyloject was launched in...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 21 Aug 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[formulation]]></category>
		<category domain="http://resources.bnet.com/topic/glasgow.html"><![CDATA[Glasgow]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/javelin+pharmaceuticals+inc..html"><![CDATA[Javelin Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/scotland.html"><![CDATA[Scotland]]></category>
		<category domain="http://resources.bnet.com/topic/u.k..html"><![CDATA[U.K.]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+congress.html"><![CDATA[U.S. Congress]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JAV</category>
		<category domain="tickers">JAV</category>
	</item>
	<item>
		<title><![CDATA[UltraShape® Commences Pivotal Study for First Non-Invasive Fat Reduction and Body Contouring Device Using Non-Thermal Selective Focused Ultrasound]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_June_12/ai_n26671430]]></link>
		<description><![CDATA[Study Will Evaluate Safety and Effectiveness of Contour Plus([TM]) Device]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 12 Jun 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Javelin Pharmaceuticals Enrolls First Patient in Pivotal Trial for PMI-150]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_June_10/ai_n25492614]]></link>
		<description><![CDATA[CAMBRIDGE, Mass. -- Javelin Pharmaceuticals, Inc. (AMEX: JAV) announced dosing of the first patient in its pivotal Phase 3 clinical study of PMI-150 intranasal ketamine for acute pain. The trial is expected to enroll approximately 200 patients and is designed to confirm the analgesic efficacy of PMI-150 in treating postoperative...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 10 Jun 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[ImmuCell Initiates Pivotal Trial of Mast Out(R)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200806/ai_n25480364]]></link>
		<description><![CDATA[ImmuCell Corporation (NASDAQ: ICCC) today announced that it has initiated the pivotal effectiveness field trial of Mast Out®. ]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 05 Jun 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[CDC Software's Pivotal CRM Helps Evangelical Christian Credit Union Improve Collaboration and Increase Client Acquisition and Retention]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_June_3/ai_n25473276]]></link>
		<description><![CDATA[Pivotal CRM Delivers 360 Degree View of Member Information So Evangelical Christian Credit Union Can Provide More Personalized Service, Improve Business Analysis, and Deepen Its Client Relationships]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 03 Jun 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/acquisition.html"><![CDATA[acquisition]]></category>
		<category domain="http://resources.bnet.com/topic/collaboration.html"><![CDATA[collaboration]]></category>
		<category domain="http://resources.bnet.com/topic/crm.html"><![CDATA[CRM]]></category>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Sciele Pharma Announces That Addrenex Has Completed Enrollment of Pivotal Phase III Trial for Clonicel for ADHD]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_June_3/ai_n25473296]]></link>
		<description><![CDATA[ATLANTA -- Sciele Pharma, Inc. (NASDAQ: SCRX), a specialty pharmaceutical company, today announced that Addrenex Pharmaceuticals has completed patient enrollment of its first Phase III clinical trial in the U.S. for Clonicel to treat attention deficit and hyperactivity disorder ADHD in children. Addrenex is also continuing to enroll patients in...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 03 Jun 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p < 0.001) in CORD I Pivotal Phase III Study for Dupuytren&#39;s Contracture]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200806/ai_n25479775]]></link>
		<description><![CDATA[Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced positive top-line efficacy and safety results from the CORD I and CORD II phase III clinical trials for XIAFLEXTM clostridial collagenase for injection in the treatment of Dupuytren's contracture. Each of the CORD I and II trials successfully met the primary endpoint, a...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 03 Jun 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/injection.html"><![CDATA[injection]]></category>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[/ CORRECTION - Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p < 0.001) in CORD I Pivotal Phase III Study for Dupuytren&#39;s Contracture]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200806/ai_n25479994]]></link>
		<description><![CDATA[In the news release, "Auxilium Pharmaceuticals, Inc. Announces XIAFLEXTM Meets Primary Endpoint With Statistical Significance (p < 0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture," issued earlier today by Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), please be advised that Marketwire incorrectly replaced the "greater than or equal to"...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 03 Jun 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[New Analyses of Pivotal Phase 3 Study of ERBITUX® Demonstrate Enhanced Efficacy in First-Line Metastatic Colorectal Cancer Patients with Wild-Type K-Ras Biomarker]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_June_1/ai_n25470596]]></link>
		<description><![CDATA[NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced data from new analyses of a pivotal Phase 3 trial that demonstrate increased efficacy of ERBITUX[R] cetuximab in first-line metastatic colorectal cancer mCRC patients with the...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Sun, 01 Jun 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Rivaroxaban Superior to U.S.-Approved Dosing Regimen for Enoxaparin in Reducing Venous Blood Clots after Total Knee Replacement Surgery in Pivotal Phase III Trial]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_May_30/ai_n25468941]]></link>
		<description><![CDATA[First Novel, Oral Anticoagulant to Consistently Demonstrate Statistically Significant Results across Four Phase III Trials]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 30 May 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Data from Pivotal Phase III Studies of Gilead's Letairis®  for Pulmonary Arterial Hypertension  in Patients with WHO Functional Class II or III Symptoms Published in Circulation]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_May_29/ai_n25467282]]></link>
		<description><![CDATA[FOSTER CITY, Calif. -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that data from the pivotal Phase III ARIES-1 and ARIES-2 studies of Letairis([R]) were published in Circulation online before print. Letairis (ambrisentan 5 mg and 10 mg tablets) is indicated as a once-daily treatment for pulmonary arterial hypertension PAH (WHO...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 29 May 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[ADVEXIN® Pivotal Phase III Data Presented as Part of Late-Breaking ASGT Presentation]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_May_29/ai_n25468642]]></link>
		<description><![CDATA[AUSTIN, Texas -- Study results from Introgen Therapeutics, Inc.'s (NASDAQ:INGN) phase III ADVEXIN([R]) (p53 tumor suppressor therapy) clinical trial were presented as a late-breaking, oral presentation earlier today at the American Society for Gene Therapy ASGT annual meeting in Boston, Mass. To access the ASGT presentation on Introgen's web site...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 29 May 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Miraculins to Conduct 2nd Pivotal Study for P2V(TM) Prostate Cancer Test]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200805/ai_n25443199]]></link>
		<description><![CDATA[Miraculins Inc. (TSX VENTURE: MOM), a biotechnology company dedicated to the discovery and development of diagnostic tools and therapeutic products for cancer, announces today that it will be conducting a 2nd pivotal pre-biopsy screen study for its urine based P2VTM prostate cancer diagnostic test. ]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 20 May 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Nomir Medical Initiates Pivotal Trial of its Noveon® Dual Wave Length Device for the Treatment of Onychomycosis]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_May_16/ai_n25430998]]></link>
		<description><![CDATA[WALTHAM, Mass. -- Nomir Medical Technologies, a leader in the development of optical energy technologies for medical applications, announced today the initiation of the pivotal product registration trial for the Company's advanced Noveon([R]) direct optical energy device. The primary objective of the trial is to test the efficacy and safety...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 16 May 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Carticept Medical Reports First Patients Treated in Pivotal Study of Agilus&#153; Therapy for Pain Associated with Ankle Osteoarthritis]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_May_14/ai_n25412019]]></link>
		<description><![CDATA[ALPHARETTA, Ga. -- Sixth graph, second sentence of release should read: The first patients were treated at Pinnacle Research in Royal Palm Beach, Florida and the Orthopedic Foot and Ankle Center in Columbus, Ohio. (sted The first patients were treated at The University of Missouri, Columbia School of Medicine and...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 14 May 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/columbus.html"><![CDATA[Columbus]]></category>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[therapy]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[CDC Software's Pivotal CRM Receives Prestigious Industry Recognition for 12th Consecutive Year]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_May_8/ai_n25399092]]></link>
		<description><![CDATA[ISM Lists Pivotal CRM 6.0 as One of the "Top 15" CRM Enterprise Packages in 2008]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 08 May 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/crm.html"><![CDATA[CRM]]></category>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Novartis Menveo(R) Vaccine Shows Superior Immune Response Against Four Types of Meningitis Disease in Pivotal Phase III Trial]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200805/ai_n25389404]]></link>
		<description><![CDATA[New Phase III data for Menveo® (MenACWY-CRM) show that the vaccine produced a greater immune response against meningococcal serogroups A, C, W-135 and Y in adolescents 11-18 years of age compared to Menactra®. Infection with any of these four vaccine-preventable serogroups can lead to bacterial meningitis, an infection of the...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 06 May 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/infection.html"><![CDATA[infection]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
</channel>
</rss>
